BPC-157
COA published
A synthetic pentadecapeptide studied in in-vitro models of tissue-repair signalling and cellular migration.
From$54.00Select size
GLOW Blend
A combined BPC-157, GHK-Cu and TB-500 preparation studied in dermal and repair research contexts.
- Test methods
- HPLC-UV + LC-MS
- Purity target
- 99%+ verified
- Sizes available
- 2
- Availability
- In stock
Select size
Quantity
1
Total
$89.00
That's the price. No inflated list, no permanent “discount” code to make it look cheaper than it is.
Certificate for this lot is pending. Every batch we ship is published at /coa before it goes out.
For Research Use Only. Not for Human Consumption.
Products supplied by Synthrex Biotech LLC are intended strictly for in-vitro laboratory research and development by qualified professionals. They are not drugs, foods, cosmetics, or dietary supplements, and are not approved by the FDA for human or veterinary use. They are not sold for, and must not be used for, human or animal consumption or administration of any kind. Synthrex Biotech LLC is not a compounding pharmacy or chemical compounding facility as defined under section 503A of the Federal Food, Drug, and Cosmetic Act, and is not an outsourcing facility as defined under section 503B of that Act. By purchasing, you affirm that you are a qualified researcher acquiring these materials for lawful research purposes only. A Safety Data Sheet (SDS/MSDS) is available on request for every compound.
Sold by Synthrex Biotech LLC. A Safety Data Sheet (SDS) is available on request at support@synthrexbiotech.com.
✦ Research Notes
Background & literature
Origin
A co-formulation of three separately characterised compounds — BPC-157, the copper tripeptide GHK-Cu (identified in human plasma by Loren Pickart in 1973), and TB-500. The blend is a supplier formulation, not a molecule described in the literature, and has no discovery history of its own.
What has been characterised
Each constituent has been characterised independently and by an unrelated mechanism: GHK-Cu as a copper(II)-binding tripeptide studied in dermal and fibroblast cell-culture models, BPC-157 in rodent angiogenic and cytoprotection models, thymosin beta-4 as a G-actin sequestering peptide in vitro. There is no published characterisation of this three-component combination as a single entity. Anything asserted about the blend is extrapolated from the separate component literatures. None of the three is FDA-approved for human use.
Sources
These notes are provided for scientific context only. They describe published laboratory and preclinical research and are not a claim of any effect in humans. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Batch releases & restocks
Know when the next batch is tested
We publish an independent certificate for every lot before it ships. Join the Lab List and we'll tell you when a new one lands and when a sold-out compound is back — plus 15% off your first order, shown on screen the second you join.
Batch and restock notices from Synthrex Biotech LLC. No dosing advice, ever. One-click unsubscribe on every email.
Related Compounds
TB-500
COA published
A thymosin beta-4 fragment investigated in research on cellular migration and angiogenesis pathways.
$50.00View
BPC-157 + TB-500 Blend
COA published
A combined preparation of BPC-157 and TB-500 used in comparative tissue-repair research models.
From$90.00Select size
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.